The Sales & Marketing Effectiveness in Chemicals Forum will bring together industry leaders as well as experts responsible and deeply involved in sales and marketing strategies.
LatAm market rising in the eyes of pharmaceutical companies
Latin America is one of the emerging regions for the pharmaceutical industry. What are the top 5 reasons?
1. It is a fast-growing region, with fast-growing economies
According to Pharmtech, by mid-2016, the number of inhabitants in Latin America will rise to 625 million, more than six million above the estimated total population in mid-2015.
The leading countries according to VisionGain's report are Brazil, Mexico, Venezuela, Argentina, Colombia and Chile. Among the leading companies are Sanofi, EMS, Novartis, Pfizer and Bayer. Representatives from three of them are currently among our speakers.
2. Innovation, affordability and availability
Facilitation of market access is possible mainly because of the Agreement for Innovation, introduced in the second half of 2012. Companies in Latin America do a lot to work with governments and make sure innovation is available. Plus, about 78% of all medicines are paid for out-of-pocket in retail pharmacies.
3. The crisis did not have such an impact here
After the crisis, more restrictions and protectionist measures were generally imposed or enhanced, which had a negative impact for multinational companies. As pharma regulatory affairs consultant María Inés Guaia says, LatAm countries are pretty inelastic: a significant share of the pharma market is managed by national health authorities and social health insurance companies that didn't significantly cut expenditure in healthcare due to the crisis.
4. The trend towards standardized regulations is increasing
While each of the previously mentioned six major markets has adopted regulations that are based on Mercosur or PAHO recommendations, international health institutes and agencies like COFERPRIS are also pushing countries towards authorizations, certification and better consistency across countries.
5. Clinical trials and R&D
Currently, an estimated 4,000 clinical trials are being conducted. Discover the future of compliance in this rising market.
Be part of the event!
2nd Annual Pharmaceutical Compliance in Latin America Congress
Interested in this topic?
Process Scale-Up in Pharma (Solid Dosage Forms)
The major objective of this course is to provide a detailed insight into the practical aspects and approaches of process scale-up for different unit operations and technologies.
Patient Adherence and Engagement
Discuss the issues of non-adherence with other stakeholders and find a solution together with the patients themselves.
Next Generation Antibody Therapeutics
This focused 2-day training will cover the discovery, engineering and production of next-generation antibodies, antibody fragments, bispecific Abs, innovative ADCs and more. Follow the path from their discovery and selection through engineering and expression to production and regulatory issues.
Turning Patient Feedback to Meaningful Resource for Care Delivery
Read the interview with Nasser Al Naimi, Deputy Chief Quality Officer at Hamad Medical Corporation, and Co-Director at Hamad Healthcare Quality Institute, and learn how to turn your data into strategic information to drive patient-family centered care.
Creating & Leading Patient Experience Excellence
Read the full interview with Dr. Ahmed Mohammad Abu-Abah, CEO at King Abdullah BinAbdulaziz University Hospital and gain insight into the creating & leading patient experience excellence.
Excelling in PV is not only about Technical Expertise
For a PV leader, to be successful can look like a daily Herculean work: meeting a crucial mandate to minimize harm to patients, while ensuring that a product is prescribed to the right population, and maintaining the highest level of compliance within a very complex set of worldwide regulations.